Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsTransforming Perioperative MIBC Care in Community Practice: Navigating Emerging Data, Guideline Changes, and Adverse Event Management Protocols
Not surprisingly, trust in government health agencies for cancer info has dipped
Response rates with daraxonrasib ranged from 31% to 37% in previously treated RAS-mutant NSCLC
News, features, and commentary about cancer-related issues
Observational study shows greater microplastic burden in patients with lung malignancy
Health news and commentary gathered by MedPage Today staff
The health ramifications of the attack persist
1.
Depression risk higher among long-term breast cancer survivors than women without breast cancer history
2.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
3.
PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC
4.
Herpes virus-based vaccine shows promise in targeting tumors without side effects
5.
Ranking of the Best US Hospitals for Psychiatric Care.
1.
New Frontiers in Diagnosing and Managing Myelodysplastic Syndromes (MASLD)
2.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
3.
Strategic Applications in Hematology in Clinical Decision-Making
4.
Obesity is a major risk factor for cancer
5.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
3.
Oropharyngeal Cancer in Relation to HPV Status
4.
Evidence-Based Oncology
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation